Aragen Bioscience and Serum Institute to work together on vaccines

A new collaboration between Aragen Bioscience and the Serum Institute of India will see the development of multiple stable cell lines in support of the latter’s HIV program.

Aragen, a subsidiary unit of GVK BIO, is a major pre-clinical contract research organization (CRO) specializing in monoclonal antibodies and other large molecules.

Serum, the world's largest vaccine manufacturer by number of doses produced and sold globally, will leverage the firm’s expertise with proprietary vectors and host cells to develop the cell lines.